Seeking Alpha

GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily...

GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily investigational medicine FF/VI for patients with chronic obstructive pulmonary disease has been accepted by the FDA, indicating the application is sufficiently complete to permit a substantive review.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)